Angex

Angex is a clinical-stage biotechnology company focused on developing novel oncology therapeutics that target the Notch signaling pathway. The company's lead candidate, AGX101, is a first-in-class antibody-drug conjugate (ADC) designed to target Delta-like ligand 4 (DLL4), a key protein involved in tumor angiogenesis and the maintenance of cancer stem cells. By utilizing a potent cytotoxic payload, AGX101 aims to provide a more effective and less toxic approach compared to earlier Notch inhibitors which faced clinical challenges. Angex is currently advancing AGX101 through Phase 1 clinical development for the treatment of various advanced solid tumors. The company was founded by a team of industry veterans with deep expertise in Notch biology and antibody development, many of whom previously led efforts at OncoMed Pharmaceuticals.